Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04836884 · ClinicalTrials.gov registry record · NA
Vascular Anomaly Pathology and Genomics Biopsy Study
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT04836884: Completed NA study, sponsored by Mayo Clinic.
NCT04836884 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04836884, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this research is to gather information on the safety and effectiveness of core biopsy of vascular anomalies for clinical pathology and clinical genomics studies.
Primary Outcome
DNA and RNA will be extracted from the biopsy specimens, undergo qualitative/quantitative quality control assessment and be analyzed by whole genome sequencing (DNA) and RNA sequence analysis (RNA-seq) to determine the adequacy of vascular anomaly biopsy for vascular anomaly genomics characterization.
Interventions
- PROCEDURE Percutaneous Vascular Anomaly/Malformation Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-04-06 |
| Est. Completion | 2022-01-31 |
| Phase | NA |
What the finished NCT04836884 record still lists
NCT04836884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Percutaneous Vascular Anomaly/Malformation Biopsy is the first listed.
NCT04836884 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04836884 about?
NCT04836884 is a clinical study titled "Vascular Anomaly Pathology and Genomics Biopsy Study". The purpose of this research is to gather information on the safety and effectiveness of core biopsy of vascular anomalies for clinical pathology and clinical genomics studies.
What is the current status of trial NCT04836884?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2021-04-06. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT04836884?
The interventions under investigation include: Percutaneous Vascular Anomaly/Malformation Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT04836884?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04836884's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI